Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review / Wrap-Ups
Year in Review
Year in Review
2023
2022
2021
LBCL 2022 Year in Review
NSCLC IO 2022 Midyear Review
AACR & ASCO 2021 – Midyear Review
Dual IO 2021 Year in Review
Year in Review
Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)
Dual IO 2021 - Year in Review
Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma.
Read More ›
Videos
Year in Review
Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
By
Sanjiv S. Agarwala, MD
Dual IO 2021 - Year in Review
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma.
Read More ›
Year in Review
Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047
Dual IO 2021 - Year in Review
First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma.
Read More ›
Year in Review
Nivolumab plus Ipilimumab as First-Line Therapy in Patients with Advanced Melanoma: 6.5-Year Update from CheckMate-067
Dual IO 2021 - Year in Review
In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals.
Read More ›
Year in Review
Nivolumab plus Relatlimab in the Neoadjuvant and Adjuvant Settings for Patients with Resectable Clinical Stage III Melanoma
Dual IO 2021 - Year in Review
Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates.
Read More ›
Videos
Year in Review
Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma
By
Sanjiv S. Agarwala, MD
Dual IO 2021 - Year in Review
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma.
Read More ›
Year in Review
Phase 2 Study of the Anti-TIGIT Antibody Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as First-Line Treatment in Patients with PD-L1–Selected NSCLC: CITYSCAPE
Dual IO 2021 - Year in Review
Treatment for NSCLC using the combination of tiragolumab plus atezolizumab was more effective than treatment with placebo plus atezolizumab.
Read More ›
Year in Review
COAST: An Open-Label, Randomized, Phase 2 Platform Study of Durvalumab Alone or in Combination with Novel Agents in Patients with Locally Advanced, Unresectable, Stage III NSCLC
Dual IO 2021 - Year in Review
Durvalumab plus either oleclumab or monalizumab improved overall response rate, progression-free survival, and 10-month progression-free survival in locally advanced, unresectable, stage III NSCLC.
Read More ›
Year in Review
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma: 3-Year Update from CheckMate-743
Dual IO 2021 - Year in Review
The phase 3 CheckMate-743 trial demonstrated survival improvement over 3 years with first-line nivolumab plus ipilimumab for patients with unresectable malignant pleural mesothelioma.
Read More ›
Videos
Year in Review
Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Combinations of novel immunotherapy agents provide benefits over standard-of-care therapy in NSCLC and malignant pleural mesothelioma.
Read More ›
Page 6 of 9
1
2
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us